Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group has adjusted the composition of its board-level committees, reinforcing its corporate governance framework. The company appointed employee representative director Ms. Ran Yongmei to the Strategy Committee and executive director Mr. Tang Yanggang to the Nomination Committee, with both changes effective from March 24, 2026.
These appointments are expected to broaden representation and executive input in strategic planning and director nomination processes, while the overall structure of the board committees remains unchanged. The move signals a fine-tuning rather than an overhaul of governance, suggesting continuity in oversight with incremental improvements to decision-making and stakeholder alignment.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company focused on the research, development, manufacturing, and distribution of medicines and healthcare products. Listed in Hong Kong, the company operates with a board structure that includes executive, non-executive, independent, and employee representative directors overseeing its strategic and governance functions.
Average Trading Volume: 774,806
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.76B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.